Your Questions Answered – Hear Directly From Dr. Cramer on What This Change Means for You
With a deep sense of gratitude for her years of dedicated service to the Multiple Sclerosis community, the MS Alliance of Virginia presents this candid and informative farewell interview with Dr. Jill Cramer. As she embarks on a new chapter, Dr. Cramer graciously shares the personal reasons behind her transition, offers crucial guidance for her patients navigating this change, and reflects on her impactful journey. We extend our sincerest thanks to Dr. Cramer for her unwavering commitment and wish her the very best in all her future endeavors.
CLICK HERE
Nerve Stimulator For Myelin Repair to Enter RRMS Clinical Trial
SetPoint Medical is planning to launch a clinical trial next year to investigate its nerve stimulator device, intending to support myelin repair, in people with relapsing-remitting multiple sclerosis (RRMS). The announcement comes after U.S. Food and Drug...
FDA Approves Ocrevus Zunovo™ as the First and Only Twice-A-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple Sclerosis
South San Francisco, CA -- September 13, 2024 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the United States Food and Drug Administration (U.S. FDA) has approved Ocrevus Zunovo™ (ocrelizumab & hyaluronidase-ocsq) for...
Human Toxicity From COVID-19 Rapid Home Test Kits
The persistence of the COVID-19 pandemic has necessitated the development and widespread availability of methods to detect the COVID-19 virus in humans. COVID-19 tests, which were initially only available in healthcare facility settings, are now manufactured for home...
Phase 1 Trial of ABA-101 for Progressive MS Gets FDA OK
Abata Therapeutics is expected to launch a Phase 1 clinical trial by the end of the year to test ABA-101, its experimental therapy for progressive multiple sclerosis (MS), after getting a green light from the U.S. Food and Drug Administration (FDA). The FDA approved...
First Healthy Participant Dosed in Phase 1 Trial of IMP761 for MS
A Phase 1 clinical trial that’s testing IMP761, an experimental treatment for multiple sclerosis (MS) and other autoimmune conditions, has dosed its first healthy participant, the therapy’s developer has announced. Immutep received regulatory clearance to start the...
The Virginia Energy Assistance Program (EAP) assists low-income households in meeting their immediate home energy needs. The EAP consists of four components: Fuel Assistance, Crisis Assistance, Cooling Assistance and Weatherization Assistance. Click on the flyer for more information.
